Please ensure Javascript is enabled for purposes of website accessibility

Why Iovance Biotherapeutics Stock Is Crashing Today

By Keith Speights - May 19, 2021 at 12:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is delaying the FDA approval filing for cell therapy lifileucel.

What happened

Shares of Iovance Biotherapeutics (IOVA -3.07%) were crashing 31.1% lower as of 11:57 a.m. EDT on Wednesday. The steep decline came after the company announced a delay in the U.S. regulatory filing for approval of cell therapy lifileucel.

So what

Iovance previously submitted data to the U.S. Food and Drug Administration (FDA) for its potency assay for lifileucel. The company received feedback from the FDA, prompting it to push back its planned filing for approval of the cell therapy from later this year to the first half of 2022.

Four scientists with unhappy expressions on their faces.

Image source: Getty Images.

Investors were understandably disappointed, causing the biotech stock to fall even more after already sinking nearly 50% below its highs from earlier this year. However, a delay isn't the same thing as a death knell. Iovance CEO Maria Fardis noted that the "FDA recognizes the unmet need for patients with metastatic melanoma who progress after anti-PD1 therapy."

Now what

Iovance now plans to continue developing and validating its potency assays. The company expects to submit additional assay data to the FDA and meet with the agency in the second half of this year. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Iovance Biotherapeutics, Inc. Stock Quote
Iovance Biotherapeutics, Inc.
$12.00 (-3.07%) $0.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.